放射组学用于胶质母细胞瘤精准医疗
本文综述放射组学与放射基因组学模型在胶质母细胞瘤诊断、分层、预后及治疗规划与监测中的研究。基于多种MRI序列、遗传信息和临床数据的分类器可较准确预测无创肿瘤诊断、总生存和治疗反应,但放射组学用于胶质母细胞瘤治疗仍处于初期,需更大样本量、标准化图像采集和数据提取技术以开发可转化至临床实践的机器学习模型。
要点
- 放射组学利用机器学习识别脑影像肿瘤特征,有望实现患者个体化管理。
- 结合MRI序列、遗传和临床数据的分类器可较准确预测诊断、总生存和治疗反应。
- 放射组学用于胶质母细胞瘤治疗仍处于初期,需更大样本和标准化技术。
核心结论
- 放射组学有潜力通过个性化医疗改变胶质母细胞瘤管理范围。
研究设计与样本
- 对现有文献进行综合综述,纳入研究放射组学和放射基因组学模型用于胶质母细胞瘤诊断、分层、预后以及治疗规划和监测的研究。
主要发现
- 基于多种MRI序列、遗传信息和临床数据组合的分类器可较准确预测无创肿瘤诊断、总生存和治疗反应。
临床怎么用
- 放射组学用于胶质母细胞瘤治疗仍处于初期,需要更大样本量、标准化图像采集和数据提取技术来开发可有效转化至临床实践的机器学习模型。
局限性
- 放射组学用于胶质母细胞瘤治疗仍处于初期,需要更大样本量、标准化图像采集和数据提取技术来开发可有效转化至临床实践的机器学习模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Being the most common primary brain tumor, glioblastoma presents as an extremely challenging malignancy to treat with dismal outcomes despite treatment. Varying molecular epidemiology of glioblastoma between patients and intra-tumoral heterogeneity explains the failure of current one-size-fits-all treatment modalities. Radiomics uses machine learning to identify salient features of the tumor on brain imaging and promises patient-specific management in glioblastoma patients. METHODS: We performed a comprehensive review of the available literature on studies investigating the role of radiomics and radiogenomics models for the diagnosis, stratification, prognostication as well as treatment planning and monitoring of glioblastoma. RESULTS: Classifiers based on a combination of various MRI sequences, genetic information and clinical data can predict non-invasive tumor diagnosis, overall survival and treatment response with reasonable accuracy. However, the use of radiomics for glioblastoma treatment remains in infancy as larger sample sizes, standardized image acquisition and data extraction techniques are needed to develop machine learning models that can be translated effectively into clinical practice. CONCLUSION: Radiomics has the potential to transform the scope of glioblastoma management through personalized medicine.
引用
- Aftab K, Aamir FB, Mallick S, et al. Radiomics for precision medicine in glioblastoma. J Neurooncol. 2022. PMID: 35020109. doi:10.1007/s11060-021-03933-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。